Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861029 · ClinicalTrials.gov registry record · Phase 1
VEG111485: A QTc Study of Pazopanib
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00861029 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2 participants.
The verdict
NCT00861029, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in subjects with solid tumors. Moxifloxacin, will serve as a positive control.
Interventions
- DRUG Moxifloxacin
- DRUG Pazopanib
- OTHER Placebo for pazopanib
- OTHER Placebo for moxifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-03-19 |
| Est. Completion | 2010-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00861029
The ClinicalTrials.gov registry entry for NCT00861029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT00861029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00861029 about?
NCT00861029 is a clinical study titled "VEG111485: A QTc Study of Pazopanib". This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in subjects with solid tumors. Moxifloxacin, will serve as a positive control.
What is the current status of trial NCT00861029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2009-03-19. Estimated completion is 2010-02-15.
What interventions are being tested in trial NCT00861029?
The interventions under investigation include: Moxifloxacin (DRUG), Pazopanib (DRUG), Placebo for pazopanib (OTHER), Placebo for moxifloxacin (OTHER).
Who is sponsoring clinical trial NCT00861029?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.